Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

External quality assessment of noninvasive fetal RHD genotyping

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Validation of a standardized donor health questionnaire across substances of human origin

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Determinants of intention to return to donate blood among first-time blood donors in Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. How donor selection criteria can be evaluated with limited scientific evidence: lessons learned from the TRANSPOSE project

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Putting the spotlight on donation-related risks and donor safety - are we succeeding in protecting donors?

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Impact of long-term storage of plasma and cell-free DNA on measured DNA quantity and fetal fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Safety of early ileostomy closure: a systematic review and meta-analysis of randomized controlled trials

    Research output: Contribution to journalReviewResearchpeer-review

  2. Prediction of ABO hemolytic disease of the newborn using pre- and perinatal quantification of maternal anti-A/anti-B IgG titer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of long-term storage of plasma and cell-free DNA on measured DNA quantity and fetal fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Targeted Rhesus immunoglobulin for RhD negative women undergoing an induced abortion: a clinical pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND OBJECTIVES: Fetal RHD genotyping of cell-free maternal plasma DNA from RhD negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 31 laboratories.

MATERIALS AND METHODS: Aliquots of pooled maternal plasma from gestational week 25 were sent to each laboratory. One sample was fetal RHD positive, and a second sample was fetal RHD negative. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. The samples were tested blindly.

RESULTS: Different methodological approaches were used; 29 laboratories used qPCR and two laboratories used ddPCR, employing a total of eight different combinations of RHD exon targets. Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD positive sample. All clinical conclusions were satisfactory.

CONCLUSION: This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting.

Original languageEnglish
JournalVox Sanguinis
Volume115
Issue number5
Pages (from-to)466-471
Number of pages6
ISSN0042-9007
DOIs
Publication statusPublished - Jul 2020

    Research areas

  • Exons, Female, Fetus/metabolism, Genotyping Techniques/standards, Humans, Plasma/chemistry, Pregnancy, Prenatal Diagnosis/standards, Real-Time Polymerase Chain Reaction, Rh-Hr Blood-Group System/blood, Rho(D) Immune Globulin, Rh prophylaxis, cell-free fetal DNA, fetal RHD genotyping, external quality assessment

ID: 61695612